Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0N2GC
|
||||
Former ID |
DIB007877
|
||||
Drug Name |
BMS-753493
|
||||
Synonyms |
Epofolate; Epothilone folate conjugate; BMS-493; BMS-748285 folate conjugate, Bristol-Myers Squibb; Targeted epothilone-folate conjugate (Endocyte technology, cancer), BMS; Targeted epothilone-folate conjugate (Endocyte technology, cancer), Bristol-Myers Squibb
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1/2 | [1], [2] | ||
Company |
Bristol-Myers Squibb Co
|
||||
Structure |
Download2D MOL |
||||
Formula |
C29H24O2
|
||||
InChI |
InChI=1S/C29H24O2/c1-29(2)19-18-24(14-10-21-6-4-3-5-7-21)26-20-23(13-17-27(26)29)9-8-22-11-15-25(16-12-22)28(30)31/h3-9,11-13,15-18,20H,19H2,1-2H3,(H,30,31)/b9-8+
|
||||
InChIKey |
YCADIXLLWMXYKW-CMDGGOBGSA-N
|
||||
CAS Number |
CAS 958646-17-8
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Folate receptor alpha | Target Info | Modulator | [3] | |
KEGG Pathway | Endocytosis | ||||
Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
Cargo concentration in the ER | |||||
WikiPathways | Folate Metabolism | ||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT00550017) A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2). U.S. National Institutes of Health. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2641). | ||||
REF 3 | A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.